Antibody binding specifically to CD40 and use thereof

Abstract

The present invention relates to an anti-CD40 antibody binding specifically to CD40 and use thereof and, particularly, provides an anti-CD40 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same antibody or fragment as an effective ingredient for prevention and/or treatment of cancer, cancer metastasis, infection, and/or immune deficiency diseases.

The invention claimed is: 
     
       1. An anti-CD40 antibody or an antigen-binding fragment thereof, comprising the following complementarity determining region (CDRs):
 CDR-H1 comprising the amino acid sequence of SEQ ID NO: 17 or SEQ ID NO: 33, 
 CDR-H2 comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 34, 
 CDR-H3 comprising the amino acid sequence of SEQ ID NO: 19, 
 CDR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 35, 
 CDR-L2 comprising the amino acid sequence of SEQ ID NO: 21 or SEQ ID NO: 36, and 
 CDR-L3 comprising the amino acid sequence of SEQ ID NO: 22. 
 
     
     
       2. The anti-CD40 antibody or the antigen-binding fragment thereof according to  claim 1 , comprising:
 a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 1, 23, 24, 25, 26, 27, or 28; and 
 a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 3, 29, or 30. 
 
     
     
       3. The anti-CD40 antibody or the antigen-binding fragment thereof according to  claim 1 , wherein the anti-CD40 antibody is an animal antibody, a chimeric antibody, or a humanized antibody. 
     
     
       4. The anti-CD40 antibody or the antigen-binding fragment thereof according to  claim 1 , wherein the antigen-binding fragment is scFv, (scFv)2, Fab, Fab′, or F(ab′)2 of the anti-CD40 antibody. 
     
     
       5. The anti-CD40 antibody or the antigen-binding fragment thereof according to  claim 1 , having an agonist activity for CD40. 
     
     
       6. A pharmaceutical composition comprising the anti-CD40 antibody or the antigen-binding fragment thereof according to  claim 1 . 
     
     
       7. A nucleic acid encoding the anti-CD40 antibody or the antigen-binding fragment thereof according to  claim 1 . 
     
     
       8. The nucleic acid according to  claim 7 , encoding either or both of:
 an amino acid sequence comprising SEQ ID NO: 17 or SEQ ID NO: 33, and SEQ ID NO: 18 or SEQ ID NO: 34, and SEQ ID NO: 19; and 
 an amino acid sequence comprising SEQ ID NO: 20 or SEQ ID NO: 35, and SEQ ID NO: 21 or SEQ ID NO: 36, and SEQ ID NO: 22. 
 
     
     
       9. The nucleic acid of  claim 7 , encoding either or both of:
 the amino acid sequence of SEQ ID NO: 1, 23, 24, 25, 26, 27, or 28; and 
 the amino acid sequence of SEQ ID NO: 3, 29, or 30. 
 
     
     
       10. A recombinant vector comprising the nucleic acid of  claim 8 . 
     
     
       11. A recombinant cell comprising the recombinant vector of  claim 10 . 
     
     
       12. An anti-CD40 antibody or an antigen-binding fragment thereof, which comprise CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of an anti-CD40 antibody produced by the hybridoma of accession number KCLRF-BP-00381. 
     
     
       13. The anti-CD40 antibody or an antigen-binding fragment thereof according to  claim 12 , which comprise a heavy chain variable region and a light chain variable region of an anti-CD40 antibody produced by the hybridoma of accession number KCLRF-BP-00381. 
     
     
       14. The anti-CD40 antibody or an antigen-binding fragment thereof according to  claim 12 , wherein the anti-CD40 antibody is produced by the hybridoma of accession number KCLRF-BP-00381. 
     
     
       15. A hybridoma, deposited with accession number KCLRF-BP-00381, for producing an anti-CD40 antibody. 
     
     
       16. A method of treating a disease, the method comprising administering the anti-CD40 antibody or the antigen-binding fragment thereof according to  claim 1  to a subject in need of treating the disease, wherein the disease is selected from the group consisting of cancer and cancer metastasis. 
     
     
       17. The method of  claim 16 , wherein the anti-CD40 antibody or the antigen-binding fragment thereof comprises:
 a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 1, 23, 24, 25, 26, 27, or 28; and 
 a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 3, 29, or 30. 
 
     
     
       18. A method of treating a disease, the method comprising administering an anti-CD40 antibody or an antigen-binding fragment thereof to a subject in need of treating the disease, wherein the disease is selected from the group consisting of cancer and cancer metastasis, wherein the anti-CD40 antibody is selected from the group consisting of:
 an anti-CD40 antibody produced by hybridoma of accession number KCLRF-BP-00381, or an antigen-binding fragment thereof; 
 an anti-CD40 antibody comprising CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of the anti-CD40 antibody produced by the hybridoma of accession number KCLRF-BP-00381, or an antigen-binding fragment thereof; 
 and an anti-CD40 antibody comprising the heavy-chain and light-chain variable regions of the anti-CD40 antibody produced by the hybridoma of accession number KCLRF-BP-00381, or an antigen-binding fragment thereof.